Geoffrey Owen
Attitudes towards the Brexit vote among science-based firms in the UK have gradually shifted from deep gloom at the start towards a more balanced assessment of what departure from the EU might mean and how it could be turned to the UK’s advantage. There is a view that an active industrial policy—what Theresa May has called a modern industrial strategy—could offset some or all of the disadvantages of non-EU membership. This is reflected, for example, in the recent report by John Bell, the government’s adviser on life sciences. He has suggested that Brexit, if carefully managed, could be used as a catalyst, setting in train a range of new measures that would speed the growth of the pharmaceutical industry in the UK.
Lisez l'article complet et bien d'autres dans ce numéro de
Prospect Magazine
Options d'achat ci-dessous
Si le problème vous appartient,
Connexion pour lire l'article complet maintenant.
Numéro unique numérique
Jan-18
 
Ce numéro et d'autres anciens numéros ne sont pas inclus dans une nouvelle version de l'article
abonnement. Les abonnements comprennent le dernier numéro régulier et les nouveaux numéros publiés pendant votre abonnement. Prospect Magazine